Everolimus, mTOR inhibitor

Be the first to review this product! Submit a review

|

(4 Publications)

MW 958.2 Da, Purity >98%. Potent mTOR inhibitor (IC₅₀ = 1.6 - 2.4 nM). Immunosupressant and anticancer activity in vivo. Orally active.

View Alternative Names

AI838772, AW493413, Atherosclerosis, susceptibility to, included, DKFZp686N23123, ER, ER-alpha, ER-beta, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen resistance, included, FK506 binding protein 12 rapamycin associated protein 1, FK506 binding protein 12 rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, FLJ11090, FLJ44809, FRAP, FRAP1, FRAP2, HDL cholesterol, augmented response of, to hormone replacement, included, MGC104252, MGC112732, MTOR_HUMAN, Mammalian target of rapamycin, Mechanistic target of rapamycin, Myocardial infarction, susceptibility to, included, NR3A1, NR3A2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, OTTHUMP00000001983, OTTHUMP00000017718, OTTHUMP00000017719, RAFT1, RAPT1, RNESTROR, RP24-311F12.2, Rapamycin and FKBP12 target 1, Rapamycin associated protein FRAP2, Rapamycin target protein, Rapamycin target protein 1, SCAN1, Serine/threonine-protein kinase mTOR, TYDP, TYDP1_HUMAN, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1)